Navigation Links
Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
Date:12/20/2011

AVENTURA, Fla., Dec. 20, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DROP), the parent company of Fuse Science, Inc. (www.fusescience.com), announced today the formal launch of its Hypoglycemic, Hyperglycemic, and  Analgesic project platforms for the advancement of its OTC and pharmaceutical licensing efforts.  

Some of the proprietary science platforms that Fuse Science deals with are oral fuse delivery technologies (OFD's). These OFD's are placed under the tongue or in the inner cheek of the patient where they are absorbed and release the applicable active or nutrient into the blood stream.  OFD's do not require water and may be more convenient to take than liquids or injections.  OFD's are especially designed to be very useful with pediatric and geriatric patients or anyone in need of faster absorption of a given active into the blood stream that bypasses the GI track, providing an alternative to the more traditional invasive drug delivery systems.

"Today we announce the further advancement of the true core of our Powered by Fuse™ technology," said Brian Tuffin, Fuse Science Chief Executive Officer. "It is with high confidence that we advance our OFD Analgesic, Hypoglycemic and Hyperglycemic project platforms with the objective of completing our pediatric and adult formulations to provide an effective sublingual and/or Buccal delivery alternative for the respective drugs."

The business opportunities from these project platforms are as follows:

  • The side effects of aspirin on the stomach include bleeding of the abdomen and deterioration of the stomach lining.  By bypassing the GI track with our drop technology we intend to improve performance and usage in the $2.5 billion adult analgesic category.
  • The largest disease state globally is diabetes with an estimated 285 million people, corresponding to 6.4% of the world's adult population living with diabetes in 2010. The number is expected to grow to 438 million by 2030, or 7.8% of the adult population. . One major issue associated with the treatment of diabetes is lack of compliance. The ease of use associated with the OFD will help address the major compliance issues in this $25 billion dollar treatment category worldwide.

"We are extremely passionate about our work in this area," said Ed Maliski, Ph.D. & Lead scientist. "Our work is born out of diabetes sufferers on staff who are committed to advancing these platforms with sense of urgency. We have produced significant results with our OFD work and feel very confident at this stage with our ability to advance these project platforms."

"We continue to be very deliberate and focused with every step we take as a company and our efforts in the OTC and Pharmaceutical space represents the foundation to our long term focus," added Tuffin.  "These actions in combination with the with the long awaited, Powered by Fuse™ EnerJel™ launch on December 30th, 2011 at www.poweredbyfuse.com are calculated steps in our effort to create long term shareholder value."

About Double Eagle Holdings
Double Eagle Holdings (OTCQB: DROP) is the parent company of Fuse Science, Inc., an innovative consumer products holding company based in Aventura, Florida.  The corporate name, Double Eagle Holdings is in the process of being changed to Fuse Science Inc.  Fuse Science is the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.  The company has successfully developed and maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly – all in a concentrated "DROP" form that is simply applied under the tongue.  The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products.  Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.



'/>"/>
SOURCE Double Eagle Holdings
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  May is Stroke Awareness Month and Omron Healthcare ... methods to prevent a stroke: monitor and manage your ... and Prevention, undetected and uncontrolled hypertension is a leading ... leader in personal heart health technology, recently evolved its ... and stroke and is advancing a national public education ...
(Date:5/4/2017)... , May 4, 2017 Clarius Mobile ... wireless, handheld ultrasound scanners this week at the ... Meeting (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians ... heart rate, and evaluate pregnancy-related complications like ectopic ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is ... back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh is ... partner with Cupron® to provide customers with a game changing chair that is ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... San Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... San Francisco, is proud to announce a new, informational blog post on insurance options. ... tooth surgery, checking insurance plans may help save time and money. Visiting an in-network ...
(Date:5/26/2017)... ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of ... Cross” is the creation of published authors, Bob and Margaret Massey. Bob Massey is ... is "panther quick and leather tough." His love for others is apparent in all ...
Breaking Medicine News(10 mins):